278 related articles for article (PubMed ID: 36415104)
1. Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Castillo JJ; Buske C; Trotman J; Sarosiek S; Treon SP
Am J Hematol; 2023 Feb; 98(2):338-347. PubMed ID: 36415104
[TBL] [Abstract][Full Text] [Related]
2. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Argyropoulos KV; Palomba ML
Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023
[TBL] [Abstract][Full Text] [Related]
3. How to Sequence Therapies in Waldenström Macroglobulinemia.
Sarosiek S; Treon SP; Castillo JJ
Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib in the management of Waldenstrom macroglobulinemia.
Yosef A; Touloukian EZ; Nambudiri VE
J Oncol Pharm Pract; 2019 Mar; 25(2):434-441. PubMed ID: 29996737
[TBL] [Abstract][Full Text] [Related]
5. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Lim KJC; Tam CS
Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
[No Abstract] [Full Text] [Related]
6. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
[TBL] [Abstract][Full Text] [Related]
7. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ
Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729
[TBL] [Abstract][Full Text] [Related]
8. Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations in Waldenström macroglobulinemia therapy: structural mechanistic insights on the role of fenebrutinib.
Elamin G; Aljoundi A; Alahmdi MI; Abo-Dya NE; Soliman MES
J Mol Model; 2022 Oct; 28(11):355. PubMed ID: 36222928
[TBL] [Abstract][Full Text] [Related]
9. Optimizing BTK Inhibition in Waldenström Macroglobulinemia.
Sarosiek S; Castillo JJ
J Natl Compr Canc Netw; 2024 May; 22(4):. PubMed ID: 38754469
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib for the treatment of Waldenström macroglobulinemia.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
Roskoski R
Pharmacol Res; 2016 Nov; 113(Pt A):395-408. PubMed ID: 27641927
[TBL] [Abstract][Full Text] [Related]
12. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.
Treon SP; Sarosiek S; Castillo JJ
Blood; 2024 Apr; 143(17):1702-1712. PubMed ID: 38211337
[TBL] [Abstract][Full Text] [Related]
13. Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia.
Muñoz J; Paludo J; Sarosiek S; Castillo JJ
Cells; 2022 Oct; 11(20):. PubMed ID: 36291152
[TBL] [Abstract][Full Text] [Related]
14. Future therapeutic options for patients with Waldenström macroglobulinemia.
Castillo JJ; Hunter ZR; Yang G; Argyropoulos K; Palomba ML; Treon SP
Best Pract Res Clin Haematol; 2016 Jun; 29(2):206-215. PubMed ID: 27825467
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
Tam CS; Ou YC; Trotman J; Opat S
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123
[No Abstract] [Full Text] [Related]
16. A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.
An G; Zhou D; Cheng S; Zhou K; Li J; Zhou J; Xie L; Jin J; Zhong L; Yan L; Guo H; Du C; Zhong J; Yu Y; Wu B; Qiu L
Clin Cancer Res; 2021 Oct; 27(20):5492-5501. PubMed ID: 34253577
[TBL] [Abstract][Full Text] [Related]
17. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
Tawfiq RK; Abeykoon JP; Kapoor P
Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
[TBL] [Abstract][Full Text] [Related]
18. Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement.
Ferrero S; Gentile M; Laurenti L; Mauro FR; Martelli M; Sportoletti P; Visco C; Zinzani PL; Tedeschi A; Varettoni M
Hematol Oncol; 2022 Aug; 40(3):332-340. PubMed ID: 35212014
[TBL] [Abstract][Full Text] [Related]
19. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.
Treon SP; Castillo JJ; Skarbnik AP; Soumerai JD; Ghobrial IM; Guerrera ML; Meid K; Yang G
Blood; 2020 May; 135(21):1912-1915. PubMed ID: 32302379
[No Abstract] [Full Text] [Related]
20. [Ibrutinib prescription in B-cell lymphoid neoplasms].
Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]